Background: The rise within the variety of most cancers circumstances and the evolution of most cancers care administration have turn out to be a big downside for the French well being care system, thereby making affected person empowerment as a protracted sought-after purpose in continual pathologies. The implementation of an activation measure through the Affected person Activation Measure-13 merchandise (PAM-13) in the midst of most cancers care can probably spotlight the affected person’s wants, with nursing care adapting accordingly.
Goal: The goals of this PARACT (PARAmedical Interventions on Affected person ACTivation) multicentric research have been as follows: (1) consider the implementation of PAM-13 in oncology nursing practices in 5 complete most cancers facilities, (2) determine the obstacles and facilitators to the implementation of PAM-13, and (3) produce suggestions for the dissemination of such interventions in different complete most cancers facilities.
Strategies: This research will comply with the “Attain, Effectiveness, Adoption, Implementation, and Upkeep” framework and can consist of three phases. First, a strong preimplementation evaluation will probably be performed utilizing the Theoretical Domains Framework (TDF) linked to the “Functionality, Alternative, Motivation, and Conduct” mannequin to determine the obstacles and facilitators to implementing new nursing practices in every context. Then, utilizing the Conduct Change Wheel, we are going to personalize a technique for implementing the PAM-13, relying on the specificities of every context, to encourage acceptability by the nursing employees concerned within the mission. This evaluation will probably be carried out through a qualitative research by way of semistructured interviews.
Second, the affected person will probably be included within the research for 12 months, throughout which the affected person care pathway will probably be studied, significantly to gather all related contacts of oncology nurses and different well being professionals concerned within the pathway. The axes of nursing care may even be collected. The first purpose is to implement PAM-13. Secondary elements to be measured are the affected person’s nervousness stage, high quality of life, and well being literacy stage. The oncology nurses will probably be liable for finishing the questionnaires when the affected person is on the hospital for his/her intravenous chemotherapy/immunotherapy remedy. The questionnaires will probably be accomplished thrice in a 12 months: (1) on the time of the affected person’s enrollment, (2) at 6 months, and (3) at 12 months. Third, a postimplementation evaluation will probably be carried out by way of semistructured interviews utilizing the TDF to research the implementation issues at every website.
Outcomes: This research was supported by a grant from the French Ministry of Well being (PHRIP PARACT 2016-0405) and the Lucien Neuwirth Institute of Cancerology of Saint-Etienne, France. Knowledge assortment for this research is ongoing.
Conclusions: This research would enhance the carried out focused nursing interventions in most cancers facilities so {that a} affected person is obtainable a customized most cancers care pathway. Moreover, measuring the extent of activation and the implementation of measures meant to extend such activation may represent a big benefit in decreasing social well being inequalities.
Navigating uncharted waters: Creating a standardized method for evaluating and implementing biosimilar merchandise at a complete most cancers middle
Goal: The processes for formulary implementation and digital well being file (EHR) integration of biosimilar merchandise at a complete most cancers middle are described. Implications for analysis protocols are additionally mentioned.
Abstract: The present literature focuses on sensible concerns for formulary addition of biosimilar merchandise, however there’s a lack of steering on how you can implement the change, significantly throughout the EHR. Earlier than constructing the ordering instruments for biosimilars, the scientific and informatics groups ought to decide the function of biosimilars on the establishment, determine drug-specific product traits that have an effect on treatment construct, and characterize implications of future formulary adjustments or drug shortages. Leveraging an orderable file supplies the power to incorporate logic that maps to a number of merchandise and in addition permits for future implementation of adjustments throughout the treatment file fairly than requiring “swaps” on the remedy protocol stage. The institutional overview board ought to coordinate adjustments in affected analysis protocols and consent kinds and work with principal investigators to amend protocols when obligatory. Pharmacy leaders ought to develop processes to supervise stock in the course of the transition interval and decrease the chance of errors.
Conclusion: The event of a standardized method for evaluating and implementing biosimilar merchandise improves effectivity and collaboration among the many numerous group members liable for the merchandise’ integration into present workflows, together with implications for scientific analysis. Implementing biosimilars for brokers used to deal with most cancers will pose new challenges and require extra concerns. Partial implementation of biosimilars continues to pose a number of challenges within the provision of affected person care.
Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version
Matrix stiffness epigenetically regulates the oncogenic activation of the Sure-associated protein in gastric most cancers
In lots of cancers, tumour development is related to elevated tissue stiffness. But, the mechanisms associating tissue stiffness with tumorigenesis and malignant transformation are unclear. Right here we present that in gastric most cancers cells, the stiffness of the extracellular matrix reversibly regulates the DNA methylation of the promoter area of the mechanosensitive Sure-associated protein (YAP). Reciprocal interactions between YAP and the DNA methylation inhibitors GRHL2, TET2 and KMT2A may cause hypomethylation of the YAP promoter and stiffness-induced oncogenic activation of YAP.
Cancer Antigen 15-3 (CA 15-3) Breast Tumor Standard Grade |
GWB-F0C8B0 |
GenWay Biotech |
25000 Unit |
Ask for price |
Cancer Antigen 125 (CA 125) Standard Grade |
GWB-565817 |
GenWay Biotech |
25000 Unit |
Ask for price |
|
Cancer Antigen 125 (CA 125) Standard Grade |
GWB-A9985A |
GenWay Biotech |
50000 Unit |
Ask for price |
Cancer Antigen 72-4 (CA 72-4) Standard Grade |
GWB-626B6B |
GenWay Biotech |
10 KU |
Ask for price |
Cancer Antigen 72-4 (CA 72-4) Standard Grade |
GWB-254330 |
GenWay Biotech |
50000 Unit |
Ask for price |
|
Cancer Antigen 19-9 (CA 19-9) Standard Grade |
GWB-1CA918 |
GenWay Biotech |
50000 Unit |
Ask for price |
|
Cancer Antigen 19-9 (CA 19-9) Standard Grade |
GWB-EECE0C |
GenWay Biotech |
50000 Unit |
Ask for price |
Human Breast Tumor Cancer Cells |
ABC-HP013X |
AcceGen |
1 vial |
Ask for price |
|
Description: Human breast cancer cells are isolated from human invasive ductal breast carcinoma sample. Human breast cancer cells are positive for pan-Cytokeratin, MGB-1 and MUC-1. CD90 staining shows that cultures are free of fibroblasts in 99%. |
Cancer Antigen 15-3 (CA 15-3) Low Cross Grade |
GWB-E47BC0 |
GenWay Biotech |
10000 Unit |
Ask for price |
Breast Tumor Antigen |
30C-CP1096B |
Fitzgerald |
50 KU |
EUR 733 |
|
Description: Partially Purified Native Breast Tumor Antigen |
Human Cancer PrimaCell4: Breast Tumor Cells |
2-96027 |
CHI Scientific |
1 Kit |
Ask for price |
Breast tumor antigen (CA-15-3) Antibody, Concentrate |
MAB521C |
Innovex |
0.2ml |
EUR 455 |
Cancer Antigen 15-3 (CA 15-3) Cell Culture Low Cross Grade |
GWB-553B7B |
GenWay Biotech |
10000 Unit |
Ask for price |
|
Human Cancer Antigen CA15-3 Antigen Grade |
GWB-C54ECC |
GenWay Biotech |
50000 Unit |
Ask for price |
Breast Cancer Antigen CA15-3 Enzyme Immunoassay Test Kit |
GWB-150A4D |
GenWay Biotech |
ELISA_Kits |
Ask for price |
|
Breast tumor antigen (CA-15-3) Antibody, Ready-To-Use |
MAB521P |
Innovex |
5ml |
EUR 445 |
Human Cancer PrimaCell4: Breast Tumor Cells Growth Medium |
9-46027 |
CHI Scientific |
5 x 100 ml |
Ask for price |
Standard grade - 601, Dia/Size in cm 15 |
6010-1500-100C |
EWC Diagnostics |
1 unit |
EUR 16.27 |
Description: Standard grade - 601, Dia/Size in cm 15 |
Standard grade - 610, Dia/Size in cm 15 |
6100-1500-100C |
EWC Diagnostics |
1 unit |
EUR 32.68 |
Description: Standard grade - 610, Dia/Size in cm 15 |
Standard grade - 961, Dia/Size in cm 15 |
9610-1500-100C |
EWC Diagnostics |
1 unit |
EUR 44.54 |
Description: Standard grade - 961, Dia/Size in cm 15 |
Breast cancer and normal tissue array with stage and grade info |
BR8012 |
TissueArray |
each |
EUR 306 |
Description: Breast cancer and normal tissue array with stage and grade info, 40 cases/80 cores, replaced by BR8014 |
Breast Cancer-Associated Antigen BRCAA1 (BRCAA1) Antibody |
20-abx148333 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Human Cancer Tissue Preparation Buffer 4: Breast Tumor Cells |
9-80027 |
CHI Scientific |
1 x 100 ml |
Ask for price |
BSA (Standard Grade) |
30-AB70 |
Fitzgerald |
1 kg |
EUR 875 |
|
Description: Standard Grade Bovine Serum Albumin (99% pure) |
Human tumor marker CA549 for breast cancer ELISA Kit |
SL3271Hu |
Sunlong |
96 Tests |
EUR 468 |
|
Standard grade - 54, Dia/Size in cm 15 R |
0540-1500-100C |
EWC Diagnostics |
1 unit |
EUR 57.8 |
Description: Standard grade - 54, Dia/Size in cm 15 R |
Standard grade - 55, Dia/Size in cm 15 R |
0550-1500-100C |
EWC Diagnostics |
1 unit |
EUR 69.48 |
Description: Standard grade - 55, Dia/Size in cm 15 R |
Standard grade - 74, Dia/Size in cm 15 R |
0740-1500-100C |
EWC Diagnostics |
1 unit |
EUR 54.94 |
Description: Standard grade - 74, Dia/Size in cm 15 R |
Breast fibroadenoma, breast tissue and breast cancer array, including pathology grade, TNM and clinical stage, 71 cases/80 cores |
BR8010 |
BioCoreUSA |
row: 8; column: 10; cores: 80; cases: 71 |
EUR 306 |
Description: Breast fibroadenoma, breast tissue and breast carcinoma microarray, containing 7 cases of normal breast, 3 adjacent normal breast tissue, 20 fibroadenoma, 10 invasive lobular carcinoma, 30 invasive ductal carcinoma and 10 matched or matched lymph node metastatic carcinoma, single core per block |
Gastrointestinal Cancer Antigen (CA 19-9), antigen grade |
CA1991-N-10 |
Alpha Diagnostics |
10 KU |
EUR 634.8 |
Cancer Antigen 125 (CA 125) Low Cross Grade |
GWB-87F2DB |
GenWay Biotech |
10000 Unit |
Ask for price |
Cancer Antigen CA50, Calibrator Grade Protein |
GWB-T00050 |
GenWay Biotech |
50KU |
Ask for price |
OPMA04167-50KIU - Human Cancer Antigen CA15-3 Antigen Grade Protein |
OPMA04167-50KIU |
Aviva Systems Biology |
50KU |
EUR 2999 |
|
Breast Cancer and 8 types of tumor (middle advanced stage)tissue array |
BR20838a |
TissueArray |
each |
EUR 474 |
Description: Breast Cancer and 8 types of tumor (middle advanced stage)tissue array, including pathology grade, TNM/stage with IHC Her-2 results, 118 cases/208 cores (core size 1.5mm), replacing BR20838 |
Tryptase Human Standard Grade |
GWB-4CE407 |
GenWay Biotech |
0.1 mg |
Ask for price |
|
Breast cancer with matched breast tissue array, including pathology grade, TNM and clinical stage, 12 cases/24 cores |
FMG252 |
BioCoreUSA |
row: 4; column: 6; cores: 24; cases: 12 |
EUR 78 |
Description: Breast carcinoma with matched breast tissue microarray, containing 12 cases breast carcinoma with matched cancer adjacent breast tissue, duplicate cores per case |
Breast cancer with breast tissue array, including pathology grade, TNM and clinical satge, 31 cases/50 cores |
BRE502 |
BioCoreUSA |
row: 6; column: 9; cores: 50; cases: 31 |
EUR 162 |
Description: Breast carcinoma with breast tissue microarray, containing 16 cases of invasive carcinoma of no special type, 1 invasive lobular carcinoma, 3 medullary carcinoma, 4 invasive carcinoma, 1 metaplastic carcinoma, plus 25 adjacent normal or cancer adjacent breast tissue (19 matched with cancer), single core per block |
Cancer Antigen CA242 (Gastrointestinal Cancer) Calibrator Grade Protein |
GWB-T00229 |
GenWay Biotech |
50KU |
Ask for price |
Breast cancer tissue array (pathology grade:1,2,3), including pathology grade, TNM and clinical stage, 45 cases/90 cores |
BR901 |
BioCoreUSA |
row: 9; column: 10; cores: 90; cases: 45 |
EUR 270 |
Description: Breast invasive carcinoma of no special type tissue microarray, containing 40 cases of invasive carcinoma of no special type, 5 adjacent normal breast tissue, duplicate core per case |
Breast cancer tissue array, with adjacent normal tissue and cancer adjacent breast tissue, including pathology grade,TNM and clinical stage, 45 cases/63 cores |
FMG631 |
BioCoreUSA |
row: 7; column: 9; cores: 63; cases: 45 |
EUR 270 |
Description: Breast invasive carcinoma of no special type tissue microarray, containing 21 cases of invasive carcinoma of no special type, with adjacent normal and cancer adjacent breast tissue (18 matched with cancer), single core per block |
Transferrin Receptor Standard Grade |
GWB-CDE6A4 |
GenWay Biotech |
1 mg |
Ask for price |
Cancer Antigen 27-29 (CA 27-29) Low Cross Grade |
GWB-16367E |
GenWay Biotech |
10000 Unit |
Ask for price |
|
Florisil@ -200 Mesh Standard Grade |
F01454 |
Pfaltz & Bauer |
100G |
EUR 229.1 |
Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 75 cases/150 cores, replacing BR1504b |
BR1504c |
BioCoreUSA |
row: 10; column: 15; cores: 150; cases: 75 |
EUR 306 |
Description: Breast carcinoma with breast tissue microarray, containing 70 cases of invasive ductal carcinoma, 4 adjacent normal breast tissue and 1 breast tissue, duplicate cores per case (duplicated cores from the same patient were put onto upper and lower rows in the same position) |
Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 188 cases/208 cores, replacing BR2085b |
BR2085c |
BioCoreUSA |
row: 13; column: 16; cores: 208; cases: 188 |
EUR 546 |
Description: Breast carcinoma with breast tissue microarray, containing 144 cases of invasive carcinoma of no special type, 24 invasive lobular carcinoma, 1 breast tissue, 19 adjacent normal breast tissue, single core per case of carcinoma, duplicate cores per case of breast tissue and adjacent normal breast tissue |
Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T087c |
FBR087d |
BioCoreUSA |
row: 3; column: 8; cores: 24; cases: 6 |
EUR 66 |
Description: Breast carcinoma with breast tissue microarray, containing 3 cases of invasive carcinoma of no special type, 1 invasive lobular carcinoma, 2 breast tissue, quadruple cores per case, 2 serial sections, divided into two identical 12 core arrays for testing different antibody dilutions |
Breast Tumor Tissue Array - 16 cases of breast cancer, each in duplicates, paired with adjacent normal tissues |
Z7020007 |
Biochain |
5 slides |
EUR 1657.2 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Circulating tumor cell breast cancer detection kit
(anti-HER-2 Ab Magbeads) |
E601CM003 |
EnoGene |
20 tests |
EUR 2500 |
Standard grade - 610, Dia/Size in cm12.5 |
6100-1250-100C |
EWC Diagnostics |
1 unit |
EUR 20.85 |
Description: Standard grade - 610, Dia/Size in cm12.5 |
Standard grade - 961, Dia/Size in cm12.5 |
9610-1250-50C |
EWC Diagnostics |
1 unit |
EUR 14.2 |
Description: Standard grade - 961, Dia/Size in cm12.5 |
Standard grade - 961, Dia/Size in 46x57 |
9610-4657-100S |
EWC Diagnostics |
1 unit |
EUR 424.61 |
Description: Standard grade - 961, Dia/Size in 46x57 |
Breast cancer |
BR1008b |
TissueArray |
each |
EUR 306 |
Description: Breast cancer, lymph node metastatic carcinoma and adjacent normal tissue array, including pathology grade, TNM, clinical stage, and ER/PR/Her2 result, 100 cases/100 cores, replacing BR1008a |
Breast cancer |
BR724 |
TissueArray |
each |
EUR 270 |
Description: Breast cancer, adjacent and adjacent normal tissue array, 66 cases/72 cores |
Breast cancer |
BR725 |
TissueArray |
each |
EUR 270 |
Description: Breast cancer, adjacent and adjacent normal tissue array, 68 cases/72 cores |
Cancer Antigen 125 (CA 125) High Purity Low Cross Grade |
GWB-12E060 |
GenWay Biotech |
20000 Unit |
Ask for price |
|
Cancer Antigen 125 (CA 125) Cell Culture Low Cross Grade |
GWB-143910 |
GenWay Biotech |
25000 Unit |
Ask for price |
|
Breast cancer with matched breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing BR251c |
BR251d |
BioCoreUSA |
row: 3; column: 8; cores: 24; cases: 6 |
EUR 48 |
Description: Breast carcinoma with matched breast tissue microarray, containing 6 cases invasive carcinoma of no special type and matched cancer adjacent or adjacent normal breast tissue, quadruple cores per case |
Breast cancer and breast tissue array, with metastatic carcinoma, including pathology grade, TNM and clinical stage, 96 cases/100 cores |
FMG1001 |
BioCoreUSA |
row: 10; column: 10; cores: 100; cases: 96 |
EUR 258 |
Description: Breast cancer and breast tissue microarray, contaning 44 cases of invasive carcinoma of no special type, 5 medullary carcinoma, 1 neuroendocrine carcinoma, 37 metastatic invasive carcinoma of no special type, 2 metastatic lobular carcinoma, 1 metastatic medullary carcinoma, 3 breast tissue, 7 adjacent normal breast tissue, single core per block |
Breast cancer tissue array with adjacent normal breast tissue, including pathology grade, TNM and clinical stage, 75 cases/150 cores |
FMG1504 |
BioCoreUSA |
row: 10; column: 15; cores: 150; cases: 75 |
EUR 306 |
Description: Breast carcinoma tissue microarray with adjacent normal breast tissue, containing 70 cases of invasive carcinoma of no special type, 5 cases of adjacent normal breast tissue, duplicate cores per case (duplicated cores from the same patient were put onto upper and lower rows in the same position) |
Breast cancer with matched breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing BR251b |
FMG251c |
BioCoreUSA |
row: 3; column: 8; cores: 24; cases: 6 |
EUR 48 |
Description: Breast carcinoma with matched breast tissue microarray, containing 6 cases invasive carcinoma of no special type and matched cancer adjacent or adjacent normal breast tissue, quadruple cores per case |
Breast cancer with cancer adjacent breast tissue array |
BC081116e |
TissueArray |
each |
EUR 306 |
Description: Breast cancer with cancer adjacent breast tissue array, including invasive carcinoma of no special type, breast carcinoma with apocrine differentiation and AT tissue,pat hology grade, IHC (ER/PR/Her-2/Ki67) info, TNM/Stage (AJCC 7th edition), 107 cases/110 cores (core size 1.5mm), replacing BC081116d |
Breast cancer tissue array, including pathology grade, TNM and clinical stage, 54 cases/108 cores |
BR1081 |
BioCoreUSA |
row: 11; column: 10; cores: 108; cases: 54 |
EUR 306 |
Description: Breast carcinoma tissue microarray, containing 52 cases of invasive carcinoma of no special type, 1 each of carcinoid and medullary carcinomag, duplicate core per case |
Breast cancer tissue array, including pathology grade, TNM and clinical stage, 64 cases/ 64 cores |
BR641 |
BioCoreUSA |
row: 8; column: 8; cores: 64; cases: 64 |
EUR 270 |
Description: Breast invasive carcinoma of no special type tissue microarray, containing 64 cases of invasive carcinoma of no special type, single core per case |
Breast cancer tissue array, including pathology grade, TNM and clinical stage, 24 cases/72 cores |
BR727 |
BioCoreUSA |
row: 8; column: 9; cores: 64; cases: 64 |
EUR 306 |
Description: Breast invasive carcinoma of no special type tissue microarray, containing 21 cases invasive carcinoma of no special type, 3 normal breast tissue, triplicate core per case |
Breast cancer tissue array, including pathology grade, TNM and clinical stage, 114 cases/114 cores |
FMG1141 |
BioCoreUSA |
row: 11; column: 11; cores: 114; cases: 114 |
EUR 354 |
Description: Breast carcinoma tissue microarray, containing 96 invasive carcinoma of no special type, 7 medullary carcinoma, 7 invasive lobular carcinoma, 3 apocrine carcinoma, 1 invasive micropapillary carcinoma, single cores per case |
Breast cancer tissue array, including pathology grade, TNM and clinical stage, 75 cases/150 cores |
FMG1503 |
BioCoreUSA |
row: 10; column: 15; cores: 150; cases: 75 |
EUR 354 |
Description: Breast invasive carcinoma of no special type tissue microarray, containing 3 cases of cancer adjacent tissue, 1 fibroadenoma, 3 phyllodes tumor, 1 carcinoma in situ, plus 60 invasive carcinoma of no special type, duplicate cores per case |
Breast cancer tissue array, including pathology grade, TNM and clinical stage, 104 cases/208 cores |
FMG2088 |
BioCoreUSA |
row: 13; column: 16; cores: 208; cases: 104 |
EUR 474 |
Description: Breast carcinoma tissue microarray, containing 97 cases of invasive carcinoma of no special type, 2 invasive lobular carcinoma, 3 medullary carcinoma,1 eachof apocrine carcinoma and mixed carcinoma, duplicate cores per case |
Breast cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases/48 cores |
FMG484 |
BioCoreUSA |
row: 6; column: 8; cores: 48; cases: 48 |
EUR 204 |
Description: Breat invasive carcinoma of no special type tissue microarray, containing 48 cases of invasive carcinoma of no special type, single core per case |
Breast cancer tissue array, including pathology grade, TNM and clinical stage, 50 cases/ 50 cores |
FMG501 |
BioCoreUSA |
row: 5; column: 10; cores: 50; cases: 50 |
EUR 270 |
Description: Breast invasive carcinoma of no special type tissue microarray, containing 50 cases of invasive carcinoma of no special type, single cores per case |
Breast cancer tissue array, including pathology grade, TNM and clinical stage, 72 cases/72 cores |
FMG721 |
BioCoreUSA |
row: 8; column: 9; cores: 72; cases: 72 |
EUR 270 |
Description: Breast carcinoma tissue microarray, containing 45 cases of invasive carcinoma of no special type, 3 lobular-ductal mixed carcinoma, 10 each of lobular carcinoma and medullary carcinoma, 4 metaplastic carcinoma, single core per case |
Standard grade - 131, Dia/Size in cm 4.7 |
1310-0470-100C |
EWC Diagnostics |
1 unit |
EUR 82.59 |
Description: Standard grade - 131, Dia/Size in cm 4.7 |
Standard grade - 161, Dia/Size in cm 4.7 |
1610-0470-100C |
EWC Diagnostics |
1 unit |
EUR 88.63 |
Description: Standard grade - 161, Dia/Size in cm 4.7 |
Standard grade - 601, Dia/Size in cm 11 |
6010-1100-100C |
EWC Diagnostics |
1 unit |
EUR 11.84 |
Description: Standard grade - 601, Dia/Size in cm 11 |
Standard grade - 601, Dia/Size in cm 12. |
6010-1250-100C |
EWC Diagnostics |
1 unit |
EUR 12.79 |
Description: Standard grade - 601, Dia/Size in cm 12. |
Standard grade - 601, Dia/Size in cm 46 |
6018-4657-100S |
EWC Diagnostics |
1 unit |
EUR 197.06 |
Description: Standard grade - 601, Dia/Size in cm 46 |
Standard grade - 613, Dia/Size in cm 4.7 |
6130-0470-100C |
EWC Diagnostics |
1 unit |
EUR 7.89 |
Description: Standard grade - 613, Dia/Size in cm 4.7 |
Standard grade - 613, Dia/Size in cm 7.5 |
6130-0750-100C |
EWC Diagnostics |
1 unit |
EUR 8.69 |
Description: Standard grade - 613, Dia/Size in cm 7.5 |
Standard grade - 613, Dia/Size in cm 11 |
6130-1100-100C |
EWC Diagnostics |
1 unit |
EUR 11.53 |
Description: Standard grade - 613, Dia/Size in cm 11 |
Standard grade - 613, Dia/Size in cm 50 |
6130-5050-100S |
EWC Diagnostics |
1 unit |
EUR 169.94 |
Description: Standard grade - 613, Dia/Size in cm 50 |
Standard grade - 615, Dia/Size in cm 12. |
6150-1250-100C |
EWC Diagnostics |
1 unit |
EUR 18.27 |
Description: Standard grade - 615, Dia/Size in cm 12. |
Standard grade - 615, Dia/Size in cm 18. |
6150-1850-100C |
EWC Diagnostics |
1 unit |
EUR 33.29 |
Description: Standard grade - 615, Dia/Size in cm 18. |
Standard grade - 615, Dia/Size in cm 46 |
6150-4657-100S |
EWC Diagnostics |
1 unit |
EUR 197.98 |
Description: Standard grade - 615, Dia/Size in cm 46 |
Standard Grade -631 , Dia/size in cm 7 |
6310-0700-100C |
EWC Diagnostics |
1 unit |
EUR 10.42 |
Description: Standard Grade -631 , Dia/size in cm 7 |
Standard Grade -631 , Dia/size in cm 9 |
6310-0900-100C |
EWC Diagnostics |
1 unit |
EUR 11.84 |
Description: Standard Grade -631 , Dia/size in cm 9 |
Standard grade - 631, Dia/Size in cm 12. |
6310-1250-100C |
EWC Diagnostics |
1 unit |
EUR 17.84 |
Description: Standard grade - 631, Dia/Size in cm 12. |
Standard Grade =642 , Dia/size in 7 cm |
6420-0700-100C |
EWC Diagnostics |
1 unit |
EUR 13.41 |
Description: Standard Grade =642 , Dia/size in 7 cm |
Standard Grade =642 , Dia/size in 9 cm |
6420-0900-100C |
EWC Diagnostics |
1 unit |
EUR 13.41 |
Description: Standard Grade =642 , Dia/size in 9 cm |
Standard Grade =642 , Dia/size in 11 cm |
6420-1100-100C |
EWC Diagnostics |
1 unit |
EUR 14.86 |
Description: Standard Grade =642 , Dia/size in 11 cm |
Standard grade - 642, Dia/Size in cm 12. |
6420-1250-100C |
EWC Diagnostics |
1 unit |
EUR 16.27 |
Description: Standard grade - 642, Dia/Size in cm 12. |
Standard grade - 642, Dia/Size in cm 46 |
6428-4657-100S |
EWC Diagnostics |
1 unit |
EUR 954.89 |
Description: Standard grade - 642, Dia/Size in cm 46 |
Standard grade - 961, Dia/Size in cm 9 |
9610-0900-100C |
EWC Diagnostics |
1 unit |
EUR 22.26 |
Description: Standard grade - 961, Dia/Size in cm 9 |
Standard grade - 961, Dia/Size in cm 11 |
9610-1100-100C |
EWC Diagnostics |
1 unit |
EUR 26.7 |
Description: Standard grade - 961, Dia/Size in cm 11 |
Standard grade - 961, Dia/Size in cm 12. |
9610-1250-100C |
EWC Diagnostics |
1 unit |
EUR 32.68 |
Description: Standard grade - 961, Dia/Size in cm 12. |
Proteinase K, Recombinant, Standard Grade |
9250-100 |
Biovision |
each |
EUR 124.8 |
Proteinase K, Recombinant, Standard Grade |
9250-10G |
Biovision |
each |
EUR 4627.2 |
Proteinase K, Recombinant, Standard Grade |
9250-1G |
Biovision |
each |
EUR 548.4 |
Proteinase K, Recombinant, Standard Grade |
9250-500 |
Biovision |
each |
EUR 314.4 |
Proteinase K, Recombinant, Standard Grade |
9251-100 |
Biovision |
each |
EUR 1266 |
Proteinase K, Recombinant, Standard Grade |
9251-25 |
Biovision |
each |
EUR 352.8 |
Proteinase K, Recombinant, Standard Grade |
9251-5 |
Biovision |
each |
EUR 144 |
Standard Grade-610, Dia/size in 7 cm |
6100-0700-100C |
EWC Diagnostics |
1 unit |
EUR 13.41 |
Description: Standard Grade-610, Dia/size in 7 cm |
CancerSeq™ Paraffin Tissue Tumor Block: Breast |
T2235086-SB |
Biochain |
1 Block |
EUR 4215 |
(untagged)-Human serologically defined breast cancer antigen NY-BR-96 mRNA, complete cds |
SC313428 |
Origene Technologies GmbH |
10 µg |
Ask for price |
CancerSeq™ Paraffin Tissue Tumor Slides: Breast |
T2235086-ST |
Biochain |
5 Slides |
EUR 601 |
Standard grade - 601, Dia/Size in cm 7 R |
6010-0700-100C |
EWC Diagnostics |
1 unit |
EUR 15.8 |
Description: Standard grade - 601, Dia/Size in cm 7 R |
Standard grade - 601, Dia/Size in cm 9 R |
6010-0900-100C |
EWC Diagnostics |
1 unit |
EUR 10.42 |
Description: Standard grade - 601, Dia/Size in cm 9 R |
Standard grade - 613, Dia/Size in cm 7 R |
6130-0700-100C |
EWC Diagnostics |
1 unit |
EUR 8.69 |
Description: Standard grade - 613, Dia/Size in cm 7 R |
Standard grade - 613, Dia/Size in cm 9 R |
6130-0900-100C |
EWC Diagnostics |
1 unit |
EUR 9.79 |
Description: Standard grade - 613, Dia/Size in cm 9 R |
Breast cancer tissue array with normal breast tissue, including pathology grade, TNM, clinical stage and Her-2 results, 5 cases/5 cores |
BRC051 |
BioCoreUSA |
row: 1; column: 5; cores: 5; cases: 5 |
EUR 42 |
Description: Breast invasive carcinoma of no special type microarray, containing 4 casee of breast invasive carcinoma of no special type and 1 normal breast tissue, single core per case |
Standard grade - 54, Dia/Size in cm 12.5 |
0540-1250-100C |
EWC Diagnostics |
1 unit |
EUR 44.54 |
Description: Standard grade - 54, Dia/Size in cm 12.5 |
Standard grade - 54, Dia/Size in cm 18.5 |
0540-1850-100C |
EWC Diagnostics |
1 unit |
EUR 101.67 |
Description: Standard grade - 54, Dia/Size in cm 18.5 |
Standard grade - 55, Dia/Size in cm 11 |
0550-1100-100C |
EWC Diagnostics |
1 unit |
EUR 38.04 |
Description: Standard grade - 55, Dia/Size in cm 11 |
Standard grade - 55, Dia/Size in cm 12.5 |
0550-1250-100C |
EWC Diagnostics |
1 unit |
EUR 48.17 |
Description: Standard grade - 55, Dia/Size in cm 12.5 |
Standard grade - 74, Dia/Size in cm 12.5 |
0740-1250-100C |
EWC Diagnostics |
1 unit |
EUR 41.54 |
Description: Standard grade - 74, Dia/Size in cm 12.5 |
Standard grade - 94, Dia/Size in cm 7 |
0940-0700-100C |
EWC Diagnostics |
1 unit |
EUR 22.26 |
Description: Standard grade - 94, Dia/Size in cm 7 |
Standard grade - 94, Dia/Size in cm 12.5 |
0940-1250-100C |
EWC Diagnostics |
1 unit |
EUR 41.54 |
Description: Standard grade - 94, Dia/Size in cm 12.5 |
Breast Tumor Tissue Array - duplicated 70 cases covering all the common types of breast cancer and 5 cases of normal and |
Z7020004 |
Biochain |
5 slides |
EUR 1422 |
Breast Tumor Tissue Array - Duplicated 70 cases covering all the common types of breast cancer and 5 cases of normal and |
Z7020005 |
Biochain |
5 slides |
EUR 1422 |
Breast Tumor Tissue Array - Duplicated 36 cases covering all the common types of breast cancer and 12 cases of normal an |
Z7020008 |
Biochain |
5 slides |
EUR 1657.2 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Breast Tumor Tissue Array - Duplicated 36 cases covering all the common types of breast cancer and 12 cases of normal an |
Z7020009 |
Biochain |
5 slides |
EUR 1657.2 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Human Cancer PrimaCell4: Breast Tumor Cells Growth Supplements with Serum (for 500 ml medium) |
9-47027 |
CHI Scientific |
1 Set |
Ask for price |
Cancer Antigen 19-9 (CA 19-9) High Purity Iodination Grade |
GWB-453206 |
GenWay Biotech |
50000 Unit |
Ask for price |
|
Breast cancer with matched cancer adjacent breast tissue array |
BR804b |
TissueArray |
each |
EUR 306 |
Description: Breast cancer with matched cancer adjacent breast tissue array, including pathology grade, TNM, clinical stage and IHC markers (ER, PR, Her-2 and Ki67), 40 cases/80 cores, replacing BR804a |
Standard grade - 54, Dia/Size in cm 46x5 |
0540-4657-100S |
EWC Diagnostics |
1 unit |
EUR 525.21 |
Description: Standard grade - 54, Dia/Size in cm 46x5 |
Standard grade - 55, Dia/Size in cm 46x5 |
0550-4657-100S |
EWC Diagnostics |
1 unit |
EUR 819.06 |
Description: Standard grade - 55, Dia/Size in cm 46x5 |
Standard grade - 74, Dia/Size in cm 46x5 |
0740-4657-100S |
EWC Diagnostics |
1 unit |
EUR 556.3 |
Description: Standard grade - 74, Dia/Size in cm 46x5 |
Standard grade - 94, Dia/Size in cm 46x5 |
0940-4657-100S |
EWC Diagnostics |
1 unit |
EUR 531.04 |
Description: Standard grade - 94, Dia/Size in cm 46x5 |
Filamin Standard Grade From Chicken Gizzard |
GWB-955E5F |
GenWay Biotech |
0.25 mg |
Ask for price |
Breast cancer TMA |
BR602 |
TissueArray |
each |
EUR 270 |
Description: Breast cancer TMA, 3 samples have matched cancer adjacent tissue samples, including pathology grade, TNM and clinical stage (reference AJCC 8th version), 57 cases/60 cores (Core Size 1.5mm), recent tear collections |
Breast cancer with adjacent normal breast tissue array, including pathology grade, TNM and clinical stage, 72 cases/72 cores, replacing FMG08013e |
FMG08013f |
BioCoreUSA |
row: 8; column: 9; cores: 72; cases: 72 |
EUR 168 |
Description: Breast carcinoma with adjacent normal breast tissue microarray, containing 63 cases of invasive carcinoma of no special type, 6 medullary carcinoma, 3 adjacent normal breast tissue, single core per case |
Breast cancer survey tissue array (5 of 5), including TNM, clinical stage and pathology grade, 208 cases/208 cores |
BR20836 |
BioCoreUSA |
row: 13; column: 16; cores: 208; cases: 208 |
EUR 474 |
Description: Breast carcinoma tissue microarray (slide 5 of 1040 cases of breast cancer survey slide set), containing 207 cases of invasive carcinoma of no special type, 1 mucinous adenocarcinoma, single core per case |
Bovine Serum Albumin Standard Grade pH 7.0 |
GWB-555343 |
GenWay Biotech |
1 kg |
Ask for price |
|
Bovine Serum Albumin Standard Grade pH 5.2 |
GWB-AA0E82 |
GenWay Biotech |
1 kg |
Ask for price |
Bovine Serum Albumin, Standard Grade, pH 7.0 |
A0210-010 |
GenDepot |
100g |
EUR 170 |
Bovine Serum Albumin, Standard Grade, pH 7.0 |
A0210-050 |
GenDepot |
500g |
EUR 720 |
Bovine Serum Albumin, Standard Grade, pH 7.0 |
A0210-100 |
GenDepot |
1Kg |
EUR 890 |
Bovine Serum Albumin, Standard Grade, pH 7.0 |
A0210-110 |
GenDepot |
10Kg |
EUR 8100 |
Standard grade - 54, Dia/Size in cm 7 Re |
0540-0700-100C |
EWC Diagnostics |
1 unit |
EUR 22.26 |
Description: Standard grade - 54, Dia/Size in cm 7 Re |
Standard grade - 54, Dia/Size in cm 9 Re |
0540-0900-100C |
EWC Diagnostics |
1 unit |
EUR 29.67 |
Description: Standard grade - 54, Dia/Size in cm 9 Re |
Direct alteration of extracellular cues through in situ matrix softening reversed YAP exercise and the epigenetic program. Our findings recommend that epigenetic reprogramming of the mechanophysical properties of the extracellular microenvironment of stable tumours might symbolize a therapeutic technique for the inhibition of most cancers development.